GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer, following an agreement reached with Takeda Australia. This transfer of marketing authorisation is an important first step in the process for GSK to make this medicine available to Australian patients.
These press releases are intended for business journalists and analysts/investors
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
We are all deeply saddened at the devastation caused by the Australian bushfires and the impact on people and wildlife in affected communities, particularly in the states of Queensland, New South Wales, Victoria and South Australia.
Professor Brendan Crabb wins 2019 GSK Award for Research Excellence
“There is probably no more impactful contribution to human development than ridding the world of malaria,” says winner
The global GSK employee resource group for LGBTQI employees and their straight allies, known as Spectrum, was launched in Australia at an event at the company’s Pharmaceuticals headquarters in Melbourne today.
Important update for health care professionals re: expiry date of Priorix, our measles, mumps and rubella vaccine
GlaxoSmithKline Australia (GSK), in consultation with the Therapeutic Goods Administration, would like to provide the following information to ensure that there is no confusion in relation to the expiration date of measles, mumps and rubella vaccine (MMR), Priorix.
Andrew Jenkin has been appointed General Manager GSK Consumer Healthcare, ANZ. The appointment comes after GSK and Pfizer closed the transaction to create a new consumer healthcare Joint Venture yesterday.
ARNUITY ELLIPTA (fluticasone furoate), once-daily maintenance therapy for asthma reimbursed by the PBS in Australia
Policy debate needed to ensure Australia remains a global leader in public access to life saving vaccines
Australia’s National Immunisation Program (NIP) is one of the world’s best, achieving some of the highest vaccination rates in the world and supporting community protection against a wide range of vaccine preventable diseases. However, Australia’s timely access to life saving vaccines is under increasing challenge, as the system that assesses which vaccines are included on the NIP falls behind other countries on some issues and may not always match with how the community values prevention.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.